The ultra large volume wearable injectors market accounted for $1,408 million in 2018, and is expected to reach $4,066 million by 2026, registering a CAGR of 14.2% from 2019 to 2026.
Ultra large volume wearable injectors are devices specially designed to stick to the body. These devices work on different mechanisms to deliver drug to the patient through subcutaneous route over an extended period of time. Furthermore, these devices have drug reservoirs that can store drugs solution of 2ml or more then 2ml. For instance, these devices function on mechanisms such as electromechanical, mechanical, and others. In addition, the electromechanical devices work with the help of electrical motor, which is responsible to build pressure for drug delivery. However, mechanical devices use osmosis to deliver the drug to the body of the patient. Furthermore, there are different benefits associated with the use of these devices. These include better patient compliance as this eliminates the need of frequent drug administration, easy ambulation as the patient is not tethered to an IV line, self-administration which lowers the frequency of healthcare professional visits, and others. In addition, these devices are used for the treatment of various chronic conditions such as cancer, diabetes, Parkinson's diseases, and others.
The major factor that contributes toward the growth of the ultra large volume wearable injectors market include surge in prevalence of chronic disorders such as diabetes, cancer, and others. Furthermore, other factors such as benefits associated with the use of ultra large volume wearable injectors and rise in adoption of these devices across the globe fuel the growth of the market.
Moreover, surge in the demand of more advanced treatment options for chronic diseases such as diabetes contributes toward the growth of the market. In addition, increase in focus by key players toward launch of new products in the market has led to rise in collaborations within the market, which fuels the growth of the market. However, high price of ultra large volume wearable devices restrict the global ultra large volume wearable injectors market growth. In contradiction, presence of ultra large volume wearable devices in development phase, which are expected to be introduced during the forecast period is expected to provide lucrative opportunities for the players in the market.
The ultra large volume wearable injectors market is segmented on the basis of product type, application, and region to provide a detailed assessment of the market. By product type, the market is divided into electromechanical wearable injectors and others. By application, it is classified into diabetes, cancer and others. By region, the ultra large volume wearable injector market size is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Major players operating in the market include Amgen Inc., Becton, Dickinson And Company, CeQur SA, Enable Injections, Inc., Gerresheimer AG (Sensile Medical AG), Insulet Corporation, Medtronic plc., Tandem Diabetes Care, Inc., West Pharmaceutical Services, Inc., and Ypsomed Holding AG.
KEY BENEFITS FOR STAKEHOLDERS
- This report entails a detailed quantitative analysis along with the current global antihypertensive market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
- The market size and estimations are based on a comprehensive analysis of key developments in the industry.
- A qualitative analysis based on innovative products facilitates strategic business planning.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Key Market Segments
- By Product Type
o Electromechanical Wearable Injectors
- By Application
- By Region
o North America
? Rest of Europe
? South Korea
? Rest of Asia-Pacific
? Saudi Arabia
? South Africa
? Rest of LAMEA
List of key players profiled in the report
- Amgen Inc.
- Becton, Dickinson And Company
- CeQur SA
- Enable Injections, Inc.
- Gerresheimer AG (Sensile Medical AG)
- Insulet Corporation
- Medtronic plc.
- Tandem Diabetes Care, Inc.
- West Pharmaceutical Services, Inc.,
- Ypsomed Holding AG
LIST OF OTHER PLAYERS IN THE VALUE CHAIN(These players are not profiled in the report. The same will be included on request.)
- E3D Elcam Drug Delivery Devices.
- Subcuject ApS